News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
FREMONT, Calif. , Jan. 13, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the completion of its previously announced underwritten public offering of 8,625,000 shares of its common
View HTML
Toggle Summary Ardelyx Announces Pricing of Public Offering of Common Stock
FREMONT, Calif. , Jan. 7, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public
View HTML
Toggle Summary Ardelyx Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , Jan. 6, 2016 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it has commenced an underwritten public offering of up to $75,000,000 of shares of its common stock.
View HTML
Toggle Summary Ardelyx Reports Positive Clinical Results of RDX022 for the Treatment of Hyperkalemia
RDX022, Ardelyx's proprietary potassium binder, demonstrates clinically relevant fecal potassium binding in a pharmacodynamic study in healthy volunteers, supporting Phase 3 clinical plans<br>Initiation of a Phase 3 clinical program with RDX022 is expected in 2H2016<br>Conference call and webcast today at 8:00am ET
View HTML
Toggle Summary Ardelyx Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Executive Vice President and Chief Medical Officer
FREMONT, Calif. , Jan. 4, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Paul Korner , MD, MBA, joined the Company in a newly created position as Executive Vice President and
View HTML
Toggle Summary Ardelyx Reports Third Quarter 2015 Financial Results
Two key clinical development programs accelerated, tenapanor in IBS-C and RDX022 in hyperkalemia<br>Initiation of a second Phase 3 clinical trial for tenapanor in IBS-C expected December 2015<br>Results of a pharmacodynamic study expected in January 2016 for RDX022, a novel potassium binder for the treatment of hyperkalemia<br>Conference Call and Webcast Today at 8:30 a.m. ET
View HTML
Toggle Summary Ardelyx to Report Third Quarter 2015 Financial Results on November 12, 2015
FREMONT, Calif. , Oct. 29, 2015 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report third quarter 2015 financial results Thursday, November 12, 2015 .
View HTML
Toggle Summary Ardelyx Announces Upcoming Presentations for Tenapanor at the American Society of Nephrology's Kidney Week Meeting 2015
FREMONT, Calif. , Oct. 28, 2015 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced nonclinical and clinical data for tenapanor, the Company's lead product candidate which is being
View HTML
Toggle Summary Ardelyx Appoints William Bertrand, Jr. to Its Board of Directors
FREMONT, Calif. , Oct. 26, 2015 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that William Bertrand , Jr., joined the Company's Board of Directors. Mr.
View HTML
Toggle Summary Ardelyx to Present Phase 2 Data for Tenapanor in IBS-C Patients at the 2015 American College of Gastroenterology Annual Meeting
Sustained Response Results to Be Featured in Poster Presentation
View HTML